We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
Read MoreHide Full Article
Insulet Corporation (PODD - Free Report) reported adjusted earnings of 23 cents per share for first-quarter 2023, down 42.5% from the year-ago period’s reported earnings of 40 cents.
First-quarter 2023 adjusted earnings however exceeded the Zacks Consensus Estimate for adjusted earnings by 155.6%.
The quarter’s adjustment excludes a charge of $8 million associated with a voluntary medical device correction notice issued to replace the Omnipod DASH Personal Diabetes Managers.
GAAP EPS was 34 cents compared with 40 cents per share in the year-ago period.
Revenues
Revenues in the first quarter totaled $358.1 million, beating the Zacks Consensus Estimate by 8.5%. Moreover, the top line jumped 21.2% from the year-ago quarter’s number (up 23.3% at the constant exchange rate or CER). Quarterly revenues exceeded the company’s previous growth expectations of 11-14% at CER.
Segment in Detail
Insulet’s Total Omnipod revenues of $357.6 million reflected an increase of 32.7% year over year (up 34.9% at CER). International Omnipod revenues of $98.6 million rose 3.4% (up 9.6% at CER). U.S. Omnipod revenues grew 48.8% year over year to $259 million.
The Drug Delivery business revenues totaled $0.5 million, down 98.1% year over year.
Margins
Gross profit in the reported quarter was $241.5 million, up 14.7% from the prior-year quarter. Gross margin of 67.2% contracted a significant 383 basis points.
Selling, general & administrative expenses rose 26.4% to $162.7 million. Research and development expenses rose 16.2% year over year to $50.1 million.
The operating margin contracted 509 basis points to 7.7%.
Insulet Corporation Price, Consensus and EPS Surprise
Insulet exited the first quarter of 2023 with cash and cash equivalents of $620.7 million, compared with $674.7 million at the end of 2022.
2023 Guidance
Insulet has updated its guidance for 2023.
For 2023, the company has raised its revenue growth guidance to the range to 18-22%(from the earlier band of 14-19%). The Zacks Consensus Estimate for total revenues is pegged at $1.52 billion.
Insulet’s Total Omnipod revenue growth is now expected in the range of 21-25% (17-22%). The company reaffirmed its expectation of Drug Delivery revenues to fall in the range of 45-55%.
For the second quarter of 2023, Insulet projects revenue growth of 27-30%. The Zacks Consensus Estimate for total revenues is pegged at $361.1 million.
Total Omnipod revenues are likely to grow 29-32%. However, Drug Delivery revenues are expected to fall in the range of 20-25%.
Our Take
Insulet exited the first quarter of 2023 with better-than-expected earnings and revenues. The company’s performance benefited from record first-quarter U.S. revenue growth of 49% and total Omnipod growth of 35%. The company delivered a record first quarter in terms of United States and global new customer starts. Omnipod 5 continued to be a driving force of Insulet’s strong U.S. growth and in the first quarter, representing almost 95% of the company’s U.S. new customer starts.
However, the substantial fall in Drug Delivery sales is discouraging. Contraction in margins does not bode well. On a year-over-year basis, the company expects gross margin to be impacted by higher costs associated with the U.S. manufacturing ramp, product line mix due to the ramp-up of Omnipod 5 and lower drug delivery revenues. Supply chain disruptions and inflationary pressures continue to challenge business operations.
Zacks Rank and Other Key Picks
Insulet currently carries Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Edwards Lifesciences Corporation (EW - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and Johnson & Johnson (JNJ - Free Report) .
Edwards Lifesciences, carrying a Zacks Rank #2, reported first-quarter 2023 adjusted EPS of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed the same in one and came in line in the other, the average being 1.2%.
Intuitive Surgical, having a Zacks Rank #2, reported first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate by 3.4%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%.
Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 1.9%.
Johnson & Johnson reported first-quarter 2023 adjusted earnings of $2.68 per share, beating the Zacks Consensus Estimate by 6.8%. Revenues of $24.75 billion surpassed the Zacks Consensus Estimate by 5%. It currently carries a Zacks Rank #2.
Johnson & Johnson has a long-term estimated growth rate of 5.5%. JNJ’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
Insulet Corporation (PODD - Free Report) reported adjusted earnings of 23 cents per share for first-quarter 2023, down 42.5% from the year-ago period’s reported earnings of 40 cents.
First-quarter 2023 adjusted earnings however exceeded the Zacks Consensus Estimate for adjusted earnings by 155.6%.
The quarter’s adjustment excludes a charge of $8 million associated with a voluntary medical device correction notice issued to replace the Omnipod DASH Personal Diabetes Managers.
GAAP EPS was 34 cents compared with 40 cents per share in the year-ago period.
Revenues
Revenues in the first quarter totaled $358.1 million, beating the Zacks Consensus Estimate by 8.5%. Moreover, the top line jumped 21.2% from the year-ago quarter’s number (up 23.3% at the constant exchange rate or CER). Quarterly revenues exceeded the company’s previous growth expectations of 11-14% at CER.
Segment in Detail
Insulet’s Total Omnipod revenues of $357.6 million reflected an increase of 32.7% year over year (up 34.9% at CER). International Omnipod revenues of $98.6 million rose 3.4% (up 9.6% at CER). U.S. Omnipod revenues grew 48.8% year over year to $259 million.
The Drug Delivery business revenues totaled $0.5 million, down 98.1% year over year.
Margins
Gross profit in the reported quarter was $241.5 million, up 14.7% from the prior-year quarter. Gross margin of 67.2% contracted a significant 383 basis points.
Selling, general & administrative expenses rose 26.4% to $162.7 million. Research and development expenses rose 16.2% year over year to $50.1 million.
The operating margin contracted 509 basis points to 7.7%.
Insulet Corporation Price, Consensus and EPS Surprise
Insulet Corporation price-consensus-eps-surprise-chart | Insulet Corporation Quote
Cash Position
Insulet exited the first quarter of 2023 with cash and cash equivalents of $620.7 million, compared with $674.7 million at the end of 2022.
2023 Guidance
Insulet has updated its guidance for 2023.
For 2023, the company has raised its revenue growth guidance to the range to 18-22%(from the earlier band of 14-19%). The Zacks Consensus Estimate for total revenues is pegged at $1.52 billion.
Insulet’s Total Omnipod revenue growth is now expected in the range of 21-25% (17-22%). The company reaffirmed its expectation of Drug Delivery revenues to fall in the range of 45-55%.
For the second quarter of 2023, Insulet projects revenue growth of 27-30%. The Zacks Consensus Estimate for total revenues is pegged at $361.1 million.
Total Omnipod revenues are likely to grow 29-32%. However, Drug Delivery revenues are expected to fall in the range of 20-25%.
Our Take
Insulet exited the first quarter of 2023 with better-than-expected earnings and revenues. The company’s performance benefited from record first-quarter U.S. revenue growth of 49% and total Omnipod growth of 35%. The company delivered a record first quarter in terms of United States and global new customer starts. Omnipod 5 continued to be a driving force of Insulet’s strong U.S. growth and in the first quarter, representing almost 95% of the company’s U.S. new customer starts.
However, the substantial fall in Drug Delivery sales is discouraging. Contraction in margins does not bode well. On a year-over-year basis, the company expects gross margin to be impacted by higher costs associated with the U.S. manufacturing ramp, product line mix due to the ramp-up of Omnipod 5 and lower drug delivery revenues. Supply chain disruptions and inflationary pressures continue to challenge business operations.
Zacks Rank and Other Key Picks
Insulet currently carries Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Edwards Lifesciences Corporation (EW - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and Johnson & Johnson (JNJ - Free Report) .
Edwards Lifesciences, carrying a Zacks Rank #2, reported first-quarter 2023 adjusted EPS of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed the same in one and came in line in the other, the average being 1.2%.
Intuitive Surgical, having a Zacks Rank #2, reported first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate by 3.4%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%.
Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 1.9%.
Johnson & Johnson reported first-quarter 2023 adjusted earnings of $2.68 per share, beating the Zacks Consensus Estimate by 6.8%. Revenues of $24.75 billion surpassed the Zacks Consensus Estimate by 5%. It currently carries a Zacks Rank #2.
Johnson & Johnson has a long-term estimated growth rate of 5.5%. JNJ’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.9%.